No Data
No Data
Evercore Initiates OnKure Therapeutics(OKUR.US) With Buy Rating
Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $34
OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Onkure Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $34 From $40
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025